Ataxin 10 antibody

Catalog No. ABIN2856106

This Rabbit Polyclonal antibody specifically detects Ataxin 10 in WB and IHC (p). It exhibits reactivity toward Human.

Quick Overview for Ataxin 10 antibody (ABIN2856106)

Target: Ataxin 10 (ATXN10)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Ataxin 10 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Product Details anti-Ataxin 10 Antibody

Cross-Reactivity: Human

Characteristics: Rabbit Polyclonal antibody to ATXN10 (ataxin 10)
ATXN10 antibody

Purification: Purified by antigen-affinity chromatography.

Immunogen: Recombinant protein encompassing a sequence within the center region of human ATXN10. The exact sequence is proprietary.

Isotype: IgG

Application Details

Application Notes: WB: 1:500-1:3000. IHC-P: 1:100-1:1000. Optimal dilutions/concentrations should be determined by the researcher. Not tested in other applications.

Comment:

Positive Control: 293T , A431 , HeLa , HepG2 , U87-MG , SK-N-SH , IMR32 , SK-N-AS

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.78 mg/mL

Buffer: 1XPBS ( pH 7), 1 % BSA, 20 % Glycerol, 0.01 % Thimerosal

Preservative: Thimerosal (Merthiolate)

Precaution of Use: This product contains Thimerosal (Merthiolate): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.

Target Details for Ataxin 10

Target: Ataxin 10 (ATXN10)

Alternative Name: ataxin 10

Background: The autosomal dominant cerebellar ataxias (ADCAs) are a clinically and genetically heterogeneous group of disorders characterized by ataxia, dysarthria, dysmetria, and intention tremor. All ADCAs involve some degree of cerebellar dysfunction and a varying degree of signs from other components of the nervous system. A commonly accepted clinical classification (Harding, 1993) divides ADCAs into 3 different groups based on the presence or absence of associated symptoms such as brainstem signs or retinopathy. The presence of pyramidal and extrapyramidal symptoms and ophthalmoplegia makes the diagnosis of ADCA I, the presence of retinopathy points to ADCA II, and the absence of associated signs to ADCA III. Genetic linkage and molecular analyses revealed that ADCAs are genetically heterogeneous even within the various subtypes.[supplied by OMIM]

Molecular Weight: 53 kDa

Gene ID: 25814

UniProt: Q9UBB4